Cambridge-based biopharmaceutical company, Leap Therapeutics, Inc., has made waves in the cancer treatment space with its acquisition and development of innovative antibody therapies. The company's flagship product candidates include DKN-01, a monoclonal antibody that targets Dickkopf-related protein 1, currently undergoing multiple ongoing clinical trials for the treatment of esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody designed to inhibit cells expressing Claudin18.2 on their cell surfaces, now in phase I clinical trials. Additionally, Leap Therapeutics boasts two preclinical antibody programs, FL-302 and FL-501. The company has also exercised an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. Lending to the company's credibility, Leap Therapeutics was incorporated in 2011 and previously operated under the name HealthCare Pharmaceuticals, Inc. before changing its name in November 2015.